Akoya to Report First Quarter 2022 Financial Results on May 5th, 2022
Akoya Biosciences, Inc. (Nasdaq: AKYA) announced the release of its first-quarter 2022 financial results scheduled for May 5, 2022, post-market close. A conference call will follow at 5:00 p.m. ET to discuss these results. Investors can join the call by calling designated numbers or through a live webcast available on the Akoya website. The company focuses on spatial phenotyping solutions for research, impacting disease progression understanding and therapy response.
- Scheduled release of Q1 2022 financial results may provide insights into company performance.
- None.
MARLBOROUGH, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2022 after the market close on Thursday, May 5th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
Investors interested in listening to the conference call may do so by dialing (833) 562-0146 for domestic callers or (661) 567-1226 for international callers, followed by Conference ID: 7363649. A live and archived webcast of the event will be available on the “Investors” section of the Akoya website at https://investors.akoyabio.com/.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research via its key platforms: PhenoCycler™, PhenoImager™ Fusion and PhenoImager HT. To learn more about Akoya, visit www.akoyabio.com.
Investor Contact:
Priyam Shah
Sr. Director, Investor Relations
Akoya Biosciences, Inc.
investors@akoyabio.com
Media Contact:
Michelle Linn
Bioscribe, Inc.
774-696-3803
michelle@bioscribe.com
FAQ
When will Akoya Biosciences release its Q1 2022 financial results?
What is the conference call number for Akoya's financial results?
What time is the conference call for Akoya's Q1 2022 results?
